Lakefront wins FDA Orphan tag for pemphigus drug
Rhea-AI Filing Summary
Lakefront Biotherapeutics NV (LKFT) reported that the U.S. FDA granted Orphan Drug Designation to its investigational antibody gamgertamig for treatment of pemphigus, adding to existing Fast Track and Orphan Drug designations in autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig is being co-developed with Gilead Sciences.
Gamgertamig, an investigational BCMAxCD3 bispecific T cell engager for autoantibody‑driven immune diseases, is in Phase 2 studies, with entry into registrational studies expected in 2027. Ongoing Phase 1b trials in autoimmune cytopenias and seropositive autoimmune diseases are enrolling across multiple countries, and proof‑of‑concept basket studies in additional autoimmune indications are expected.
Positive
- The U.S. FDA granted Orphan Drug Designation to gamgertamig for pemphigus, expanding its prior Fast Track and Orphan designations in other autoimmune diseases and reinforcing the program’s regulatory recognition across multiple indications.
- Gamgertamig is already in Phase 2 studies with plans to enter registrational studies in 2027, indicating clinical progress toward potential late‑stage development in autoimmune diseases.
Negative
- None.
Key Figures
Orphan Drug Designation date: 24 August 2026
Clinical phase: Phase 2
Expected registrational start: 2027
+2 more
5 metrics
Orphan Drug Designation date
24 August 2026
Date Lakefront announced FDA Orphan Drug Designation for pemphigus
Clinical phase
Phase 2
Gamgertamig is currently in Phase 2 studies in autoimmune diseases
Expected registrational start
2027
Gamgertamig is expected to enter registrational studies in 2027
Phase 1b studies
2 Phase 1b studies
One in autoimmune cytopenias and one in seropositive autoimmune diseases
Existing FDA designations
Orphan Drug and Fast Track
Prior designations for AIHA and ITP
Key Terms
Orphan Drug Designation, Fast Track Designation, bispecific T cell engager, BCMAxCD3, +1 more
5 terms
Orphan Drug Designation regulatory
"U.S. FDA has granted Orphan Drug Designation to gamgertamig"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"previously granted both Fast Track and Orphan Drug Designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
bispecific T cell engager medical
"an investigational BCMAxCD3 bispecific T cell engager for the treatment"
A bispecific T cell engager is a lab-made protein that acts like a matchmaker between a cancer cell and a patient's immune killer cell (T cell), attaching to both so the T cell can recognize and destroy the cancer cell. For investors, these drugs matter because they can produce powerful, targeted effects that may lead to big clinical and commercial wins, but they also carry high development, safety and manufacturing risks that make outcomes binary and value volatile.
BCMAxCD3 medical
"a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager"
proof-of-concept basket studies medical
"Expect to initiate proof-of-concept basket studies assessing gamgertamig"
FAQ
What did Lakefront Biotherapeutics (LKFT) announce regarding gamgertamig?
Lakefront Biotherapeutics announced that the U.S. FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig already has Orphan Drug and Fast Track designations for autoimmune hemolytic anemia and immune thrombocytopenia.
What stage of development is gamgertamig in for LKFT?
Gamgertamig is currently in Phase 2 studies for autoimmune diseases and is expected to enter registrational studies in 2027, according to Lakefront Biotherapeutics.
For which diseases does gamgertamig have FDA designations?
Gamgertamig has U.S. FDA Orphan Drug Designation for pemphigus and both Fast Track and Orphan Drug Designation for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
What clinical trials of gamgertamig are ongoing for LKFT?
Ongoing Phase 1b studies include patients with autoimmune cytopenias (including ITP and AIHA, NCT07083960) and seropositive autoimmune diseases such as idiopathic inflammatory myositis, Sjögren’s disease, pemphigus vulgaris, and pemphigus foliaceus (NCT07229144).
Who is Lakefront Biotherapeutics collaborating with on gamgertamig?
Gamgertamig is being developed by Lakefront Biotherapeutics in collaboration with Gilead Sciences. The program is in‑licensed from Keymed Biosciences, which retains rights to develop it in Greater China.
What future plans did LKFT outline for gamgertamig studies?
Lakefront Biotherapeutics stated it expects to initiate proof-of-concept basket studies assessing gamgertamig in additional autoimmune indications and anticipates expansion of the clinical trials program in 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
